Included articles described hydroquinone-associated ochronosis
This does not mean injectable GHK-Cu is ineffective in humans -- it means the evidence does not yet exist to confirm or quantify its effects
Cycle Guidelines Common NAD+ Cycle Reference Approach Standard SubQ Duration 4-8 weeks Review point Week 4 Best for General research-context cellular-energy planning Approach Extended SubQ + oral bridge Duration 8-12 weeks SubQ, then 4 weeks oral NMN/NR Review point End of injectable phase Best for Layered approach combining injection and oral precursors Approach IV maintenance Duration Weekly or bi-weekly, ongoing Review point Every 4-8 weeks Best for Clinic-supervised research planning Approach IV loading + maintenance Duration 3-5 daily IV sessions, then weekly/monthly Review point After loading phase Best for Intensive clinic protocol Unlike receptor-based peptides, NAD+ is a coenzyme
Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, et al
GLOW commonly appearing as 70 mg and KLOW commonly appearing as 80 mg does not make one automatically better, stronger, or more suitable
Stimuli include irritants, allergens, exercise, infection, and weather
